Reviewing the Latest Research on Value-Based Care, Clinical Pathways, and Precision Medicine

Blood Test Predicts Survival Outcomes in Patients With Lung Cancer

A blood-based proteomic test offers prognostic information and optimal second-line treatment guidance for patients with squamous cell carcinoma of the lung.

Read More

 

Common Second-Line Treatment for Liver Cancer Not Cost-Effective

A conventional second-line treatment for hepatocellular carcinoma offers only a marginal increase in quality-adjusted life-years at a significantly high cost.

Read More

 

Immunotherapy Shows Promise in Rare Form of Lymphoma

A recent report demonstrates the promise of programmed death inhibition in improving outcomes for patients with gray zone lymphoma, a rare, difficult-to-treat type of lymphoma.

Read More

 

Chronic Cancer Survivors in Need of Improved Survivorship Care Plans

Survivors of chronic cancer are often not receiving optimal survivorship care plans and follow-up treatment.

Read More

 

CAR-T Therapy Response Independent of Disease Factors in NHL

A recent clinical trial of a chimeric antigen receptor T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive non-Hodgkin lymphoma independent of disease type, stage, or characteristics.

Read More

 

Mastectomy Not Cost-Effective for Most Patients With Ovarian Cancer

Risk-reducing mastectomy performed within 5 years of ovarian cancer diagnosis does not appear to be cost-effective when compared with surveillance for patients harboring BRCA mutations.

Read More

 

Comparing Prognostic Values of MRI or PET-CT in Multiple Myeloma

Researchers identified which imaging technique is better for evaluating prognosis of newly-diagnosed multiple myeloma.

Read More

 

Triplet Combination Shows Durable Responses in Advanced Multiple Myeloma

Patients with heavily treated multiple myeloma showed rapid and durable responses to a novel treatment combination.

Read More

 

Continued Nivolumab After Progression May Improve Melanoma Outcomes

Patients with advanced melanoma who are treated with the immunotherapeutic agent nivolumab after their first disease progression may experience tumor response without compromising safety.

Read More

 

Neoadjuvant Chemotherapy May Induce Breast Cancer Metastasis

A neoadjuvant chemotherapy combination used to treat breast cancer increases the risk of disease metastasis.

Read More